In November 2024, Bobby Mukkamala was giving a routine talk to a group of physicians and medical students when his language suddenly became garbled. For a minute or two, he stopped making any sense.
Researchers at Baylor College of Medicine and collaborating institutions investigated for the first time in cancer the association between two sources of genetic variation: germline or inherited structural variation, which refers to large differences in the DNA sequence, and DNA methylation, which is when genes are turned on or off without altering the DNA code.
Michael Chan was appointed chair of Wake Forest University’s Department of Radiation Oncology, which he has led as interim chair since 2023. In his permanent role, he will advance the clinical, research and education missions of the department, while optimizing care delivery and clinical operations.
Walter J. “Wally” Curran, Jr. has been named the Whitaker Endowed Chief of Piedmont Oncology. This bestowed title is supported by the Piedmont Foundation’s Whitaker Endowment, a fund created by the Atlanta community in tribute to Piedmont’s cancer surgical leader, William Whitaker.
Researchers at the University of Texas Health Science Center at San Antonio have discovered a way to delay or even block recurrence of the deadliest brain cancer after radiation.
Researchers and pediatric neurosurgeons at the University of Pittsburgh School of Medicine and UPMC Children’s Hospital of Pittsburgh developed a new way to profile brain cancers in children.
A protein designed by Cedars-Sinai Cancer investigators can cross the protective blood-brain barrier safely and deliver therapy directly into cancerous tumor cells, a preclinical study shows.
Researchers from Fred Hutch Cancer Center and the University of Texas MD Anderson Cancer Center have uncovered a biomarker capable of accurately predicting outcomes in meningioma brain tumors and breast cancers using a new technology and computational method.
CureSearch for Children’s Cancer awarded a $225,000 research grant to John Prensner, a physician-scientist at the University of Michigan, to advance research on atypical teratoid/rhabdoid tumors. One of the most aggressive and fatal brain cancers affecting infants and toddlers, ATRT has limited treatment options and devastating outcomes, with more than half of cases proving fatal.
Cheng-Chia “Fred” Wu, a physician-scientist who treats brain tumors in children, has joined Virginia Tech to bring his expertise in focused ultrasound cancer research to the Fralin Biomedical Research Institute at Virginia Tech Carilion.
